Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Natasha McKee

Physician Assistant, Medical Missoula, MT Physician Assistant

NPI 1144262734 CMS profile 10979562

2835 Fort Missoula Rd Bldg 3, Missoula, MT 59804

Open in the dashboard

General payments

$3,419

224 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Natasha McKee of Missoula, MT is reported in the CMS Open Payments database as having received $3,419 across 224 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $924 52
2024 General $916 58
2023 General $323 21
2022 General $582 42
2021 General $674 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Natasha McKee
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Natasha McKee were reported at $924. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Natasha McKee Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $674 $156 $41–$563 $132
2022 $582 $185 $55–$649 $149
2023 $323 $199 $58–$717 $160
2024 $916 $206 $62–$740 $164
2025 $924 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,028 99 payments
  2. Novartis Pharmaceuticals Corporation $365 19 payments
  3. Lilly USA, LLC $336 18 payments
  4. Janssen Biotech, Inc. $280 12 payments
  5. Genzyme Corporation $259 12 payments
  6. UCB, Inc. $233 12 payments
  7. Amgen Inc. $185 10 payments
  8. E.R. Squibb & Sons, L.L.C. $162 10 payments
  9. Regeneron Healthcare Solutions, Inc. $121 6 payments
  10. Pfizer Inc. $96 7 payments
  11. Other $353 19 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,320 223 payments
  2. Education $99 1 payment
Products named General payments · program years 2021–2025
  1. SKYRIZI Immunology $517 51 payments
  2. TALTZ $336 18 payments
  3. DUPIXENT $296 14 payments
  4. TREMFYA $249 11 payments
  5. RINVOQ $248 24 payments
  6. COSENTYX $213 10 payments
  7. Otezla $185 10 payments
  8. Bimzelx $185 10 payments
  9. SKYRIZI Immunology $175 12 payments
  10. SOTYKTU $162 10 payments
  11. Other $1,307 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

281

Median for Physician Assistant: 241

Drug cost

$133,057

Median for Physician Assistant: $4,110

Branded share of claims

15.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Pen Adalimumab Brand 12 $75,346
Dupixent Pen Dupilumab Brand 14 $52,176
Fluorouracil Generic 26 $1,972
Metronidazole Generic 29 $1,157
Clobetasol Propionate Generic 31 $570
Triamcinolone Acetonide Generic 64 $418
Mometasone Furoate Generic 24 $418
Spironolactone Generic 21 $329
Doxycycline Monohydrate Generic 12 $259
Imiquimod Generic 11 $162

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$132,876

Of which drugs: $7,938

Medicare patients

957

Average age 75

Services billed

4,785

621 women, 336 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 54%
Arthritis 41%
Osteoporosis 16%
Ischemic heart disease 15%
Depression 15%
Cancer 14%
Diabetes 13%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 29 32 $7,933

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $167
$167 — —
Otezla
  • Amgen Inc. $100
$100 — —
DUPIXENT
  • GENZYME CORPORATION $88
$88 14 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $79
$79 — —
AYVAKIT
  • Blueprint Medicines Corporation $58
$58 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

224 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record